COVID-19 Pandemic   WHO approved Sinopharm's COVID-19 vaccine for global use and will consider Sinovac's vaccine next week; Beijing Sinovac's inactivated COVID-19 (Vero Cell) vaccine has started a rolling review for European approval;  Deals and Financings   Shanghai Hope Medicine closed a $56 million Series B round led by Qiming Venture Partners and Grand Flight Investment to develop novel drugs; Beijing WeMed Medical completed a $46 million Series D financing to support its digital angiography medical devices; Shineco, a  China  herbal medicine company, announced plans to acquire a 51% stake in a Taiwan biotech, Mayah Biological Holdings; Trials and Approvals   BeiGene of Beijing announced  China conditional approval for its PARP inhibitor, the company's third drug approved in China ;   Shanghai Newsoara's lead drug candidate completed a successful China Phase II trial in gastrointestinal surgery patients; Galmed Pharma of Israel was approved to add a  China  arm to its global Phase III trial of Aramchol in patients with NASH and fibrosis; Ascletis Pharma of  Hangzhou  reported positive Phase IIa trial results from its PD-L1 candidate in patients with chronic hepatitis B; Beijing 's Jacobio Pharma announced  US  approval to start trials of its KRAS G12C inhibitor as a therapy for advanced solid tumors; Shanghai 's Asieris Pharma and  Beijing 's BeiGene will test a combination of Asieris' MetAP2 inhibitor and BeiGene's PD-L1 in bladder cancer patients.  Stock Symbol: (NSDQ: TYHT) (NSDQ: SVA) (NSDQ: BGNE; HK: 06160) (NSDQ: GLMD) (HK: 1672) (HK: 1167) Share this with colleagues: // //